SKI V
CAS No. 24418-86-8
SKI V( —— )
Catalog No. M21983 CAS No. 24418-86-8
SKI V is a potent and noncompetitive non-lipid sphingosine kinase (SPHK; SK) inhibitor (GST-hSK,IC50 : 2 μM), and is a PI3K inhibitor(hPI3k,IC50 : 6 μM), induces apoptosis and has antitumor activity
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 215 | In Stock |
|
| 5MG | 188 | In Stock |
|
| 10MG | 297 | In Stock |
|
| 25MG | 511 | In Stock |
|
| 50MG | 732 | In Stock |
|
| 100MG | 1079 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSKI V
-
NoteResearch use only, not for human use.
-
Brief DescriptionSKI V is a potent and noncompetitive non-lipid sphingosine kinase (SPHK; SK) inhibitor (GST-hSK,IC50 : 2 μM), and is a PI3K inhibitor(hPI3k,IC50 : 6 μM), induces apoptosis and has antitumor activity
-
DescriptionSKI V is a potent and noncompetitive non-lipid sphingosine kinase (SPHK; SK) inhibitor (GST-hSK,IC50 : 2 μM), and is a PI3K inhibitor(hPI3k,IC50 : 6 μM), induces apoptosis and has antitumor activity.
-
In VitroSKI V has weak activity toward ERK2 (IC50 of 80 μM for hERK2) and does not inhibit PKC-α.SKI V (10 μM; for 24 hours) inhibits cancer cell proliferation and induces apoptosis. SKI V (0.2, 1, 5 μM; pretreated for 1 hour) decreases phospho-Akt and phospho-MEK levels. Near-confluent cultures of JC cells are serum-starved for 16 hours, followed by pretreatment SKI V for 1 hour. SKI V has IC50s for inhibition of sphingosine kinase (SK) and tumor cell proliferation of ~2 μM. SKI V (20 μg/ml) inhibits not only purified but endogenous SK in in MDA-MB-231 cells.SKI V (0.2, 1, 5 μM) inhibits intracellular S1P formation in JC cells in a dose-dependent fashion. Cell Proliferation Assay Cell Line:T24 tumor cells Concentration:10 μM Incubation Time:For 24 hours Result:Inhibited cancer cell proliferation.Apoptosis Analysis Cell Line:T24 tumor cells Concentration:10 μM Incubation Time:For 24 hours Result:Induced apoptosis.Western Blot AnalysisCell Line:JC cells Concentration:0.2, 1, 5 μM Incubation Time:Pretreated for 1 hour Result:Decreased phospho-Akt and phospho-MEK levels.
-
In VivoSKI V (75 mg/kg; i.p.; days 1, 5, 9, 15) significantly lowers tumor growth (>50% decreased at day 18) than control animals. Animal Model:6-8 weeks old BALB/c female mice with JC mammary adenocarcinoma cellsDosage:75 mg/kg Administration:IP; days 1, 5, 9, 15 Result:Tumor growth was significantly lower (>50% decreased at day 18) than tumor growth in control animals.
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetS1P Receptor
-
RecptorSphK|PI3K
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number24418-86-8
-
Formula Weight254.24
-
Molecular FormulaC15H10O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (196.66 mM)
-
SMILESOc1ccc(\C=C2\Oc3ccccc3C2=O)cc1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. French KJ, et al. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther. 2006 Aug;318(2):596-603.2. French KJ, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003 Sep 15;63(18):5962-9.
molnova catalog
related products
-
4-Deoxypyridoxine hy...
4-Deoxypyridoxine (hydrochloride) inhibits the degradation of intracellular S1P by inhibiting S1P lyase (SPL) activity, minimized the chemically induced apoptosis of insulinoma cell lines as S1P did.
-
W140 HBr
[(3S)-3-amino-4-(3-hexylanilino)-4-oxobutyl]phosphonic acid;hydrobromide is a S1P1 antagonist with Ki of 2.84 μM.
-
MP-A08
MP-A08 is a highly selective ATP competitive inhibitor of sphingosine kinase (SPHK1) that targets both SphK1 and SphK2 (Ki: 6.9 ± 0.8 μM and 27 ± 3 μM, respectively).
Cart
sales@molnova.com